Medical AI Company JLK Aims for 600 Billion KRW Revenue by 2028 with Stroke Diagnosis AI

Medical artificial intelligence (AI) company JLK announced its goal to achieve annual sales of 600 billion KRW by 2028, with 80% of sales coming from the United States and 20% from the domestic market.

On the 9th, Kim Dong-min, CEO of JLK, held a vision declaration ceremony at the Conrad Seoul Hotel in Yeouido, Yeongdeungpo-gu, Seoul, and announced the goal of achieving 600 billion KRW in sales by 2028, with 80% from the United States and 20% from the domestic market.
Photo by Choi Tae-won paeceful1@

On the 9th, Kim Dong-min, CEO of JLK, held a vision declaration ceremony at the Conrad Seoul Hotel in Yeouido, Yeongdeungpo-gu, Seoul, and made this announcement.

JLK, established in 2014, is a medical AI company specializing in stroke. It possesses 11 related solutions, including the brain hemorrhage detection solution 'JBS-04K' and the cerebral infarction classification solution 'JBS-01K'. Among these, JBS-01K became the first in Korea last year to pass the integrated review for innovative medical devices and was applied as a non-reimbursable service.

According to JLK, stroke is a critical cause of death worldwide, with 15 million new patients annually and one death every six seconds. Additionally, 63% of stroke patients are under the age of 70, indicating a high incidence at a relatively young age.

CEO Kim said, "Compared to other diseases, stroke diagnosis requires various imaging tests, making the stroke diagnosis market size approximately 53 trillion KRW. JLK plans to replace the AI solutions currently used locally by receiving innovative reimbursement in the United States."

Professor Kim Dong-eok of the Department of Neurology at Dongguk University Ilsan Hospital, speaking as a presenter, explained, "In Korea, there is a shortage of specialists to interpret emergency patients' imaging tests during nights or weekends, causing delays and potentially reducing diagnostic accuracy. Since rapid treatment after symptom onset is crucial for stroke, it is necessary to use medical AI to resolve diagnostic delays or misdiagnoses and improve treatment effectiveness."

He continued, "As medical technology has improved compared to the past, the amount of information to analyze has greatly increased. Therefore, medical AI that can provide information at the level of stroke specialists across various medical institutions is needed. Through AI, doctors can focus on tasks more difficult than interpretation and obtain evidence for diagnosis," he emphasized.

JLK's AI solutions are known to detect ambiguous or small cerebral infarctions and classify cerebral infarctions into multiple types, helping medical staff decide which treatment methods to use.

CEO Kim said, "In just 10 months since February last year, over 210 hospitals have adopted our company's AI solutions. With the start of non-reimbursable prescriptions this year, sales are expected to rise significantly, and by 2028, JLK aims to achieve an 85% market share in the domestic market."